论文部分内容阅读
本文通过对大量文献的阅读,就可能影响重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗缺血性脑卒中患者临床预后的因素作一综述,rt-PA溶栓虽能改善患者临床预后,但受许多因素的影响,如年龄、性别、起病至溶栓治疗时间(OTT)、高血压病、溶栓时血压、糖尿病、溶栓时高血糖、房颤、卒中严重程度、抗血小板药物等,应在临床应用时充分考虑影响疗效的各种因素,进行全面评估。
This article reviews a large number of literature on the factors that may affect the clinical prognosis of patients with ischemic stroke by intravenous thrombolysis of recombinant tissue plasminogen activator (rt-PA). Although rt-PA thrombolysis Improve patient outcomes, but are affected by many factors, such as age, gender, onset to thrombolytic therapy time (OTT), hypertension, blood pressure at thrombolysis, diabetes mellitus, hyperglycemia at thrombolysis, atrial fibrillation, severe stroke Level, anti-platelet drugs, etc., should be fully considered in clinical application of various factors that affect the efficacy of a comprehensive assessment.